Elevance Health Reports Q1 GAAP EPS Decline and $935M Regulatory Accrual

summarizeSummary

Elevance Health reported a 16.8% decline in Q1 GAAP diluted EPS and recorded a $935 million accrual for Medicare Advantage risk adjustment data noncompliance, despite strong operating cash flow and continued share repurchases.

check_boxKey Events

• Significant GAAP EPS Decline

  Diluted earnings per share decreased by 16.8% to $8.00 in Q1 2026, down from $9.61 in Q1 2025, despite a 2.6% increase in total revenues.

• $935M Regulatory Accrual for Medicare Advantage

  The company recorded a $935 million accrual for potential exposure related to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements. Management estimates the liability could range from $585 million less to $565 million more than the accrued amount.

• Strong Operating Cash Flow

  Net cash provided by operating activities significantly increased to $4.332 billion in Q1 2026, up from $1.017 billion in Q1 2025, primarily due to favorable working capital impacts.

• Substantial Share Repurchases

  Elevance Health repurchased 3.7 million shares for $1.124 billion during Q1 2026, with $5.571 billion remaining under the existing authorization.

auto_awesomeAnalysis

Elevance Health's first-quarter 2026 GAAP financial results show a significant year-over-year decline in net income and diluted EPS, contrasting with the 'adjusted EPS beat' reported in a concurrent 8-K filing. This divergence between GAAP and non-GAAP performance, coupled with a substantial $935 million accrual for potential Medicare Advantage risk adjustment data noncompliance, introduces considerable financial and regulatory uncertainty. While the company demonstrated strong operating cash flow and continued its share repurchase program, the regulatory risk and core earnings decline are material concerns for investors. The wide estimated range for the CMS liability further highlights the potential for future financial impact.